The goal of this clinical trial is compare the safety and efficacy of a study medication by itself versus two other combinations, Pomalidomide, Bortezomib and Dexamethasone or Carfilzomib and Dexamethasone in participants who have relapsed or refractory multiple myeloma.
This trial is currently open and accepting patients.
This clinical trial is seeking approximately 590 patients, who will be randomly assigned into one of two different groups. You will have a 50% chance of being in either group. This study is open-label, which means that both the participants and the study team will know which group they have been placed in and which therapies they will receive. Participants may continue to participate in the study as long as their myeloma doesn’t get worse and they don’t experience bad side effects.
Group A will receive the study medication by itself. Participants in Group B will receive either Pomalidomide, Bortezomib and Dexamethasone OR Carfilzomib and Dexamethasone. The study physician will decide which combination you receive, depending on your treatment history and other factors.
The study medication used in Group A is a bispecific antibody that targets two different proteins. The two proteins are CD3 on your own T-cells, and BCMA, which is found on myeloma cells. This medication may work by bringing together your T-cells and myeloma cells in order to help your own immune system fight your myeloma.
You will not be paid for taking part in this study. You may receive reimbursement or stipend(s) to help with your expenses (e.g., mileage, parking, and/or meals) for attending study visits. If a caregiver is needed to accompany you to your study visits, your caregiver may receive reimbursement or stipend(s) to offset expenses (e.g. meals) for attending study visits with you. If applicable, travel assistance (e.g. car service, train, hotel arrangements) may be offered in lieu of reimbursement, to help you get to and from your study visits and to provide accommodations as necessary during your participation in the study. The study site will discuss the options that are available for you. Janssen is committed to Health Equity. Once assigned to a study site, please inquire about financial programs in place to support clinical trial participation.
The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.
Phase 3
Enrollment: 590 patients (estimated)
View MoreView all clinical trial locations sorted by state.
Orange, CA
Miami, FL
New York, NY
Lancaster, PA
Houston, TX
We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.
(888) 828-2206If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.
Find Nearby LocationsYou can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message
Learn more about how we work with trial sponsors